NextCure provides year-end clinical pipeline updates

NextCure provided an update on its clinical pipeline. The Phase 1b combination trial of NC410 with pembrolizumab is ongoing. The combination has been safe and well tolerated to date. Clinical data, including results from additional patients, are expected in the first half of 2024. Due to the competitive environment and the limited activity to date, NextCure does not plan to further develop NC762 and is prioritizing the development of LNCB74, the first antibody drug conjugate – ADC – candidate from the company’s collaboration with LegoChem Biosciences, and shifting resources from NC762 to the ADC program. Plans to initiate a dose range-finding toxicology study and GMP manufacturing for LNCB74 in early 2024. Regarding NC525, the Phase 1a dose escalation study in subjects with acute myeloid leukemia remains ongoing with clinical data expected in the first half of 2024.